Acromegaly Treatment Gets a Precision Medicine Makeover
A 2025 review maps current and emerging therapies for acromegaly, highlighting why ~40% of patients still lack adequate disease control.
Summary
Acromegaly, caused by excess growth hormone, drives serious complications and shortened lifespan. Surgery cures roughly half of patients, and three drug classes cover most of the rest — but around 40% still don't achieve biochemical control. This 2025 review in Endocrine Reviews surveys existing therapies (somatostatin receptor ligands, dopamine agonists, and GH receptor antagonists), examines drugs in the development pipeline, and argues for a shift toward precision medicine guided by biomarkers. The authors emphasize that even when lab values normalize, quality of life often remains impaired and treatment burden stays high. Moving away from trial-and-error prescribing toward biomarker-driven therapy selection is presented as the most promising path to better patient outcomes.
Detailed Summary
Acromegaly is a rare but serious chronic disease caused by excess growth hormone — typically from a pituitary adenoma — leading to disfigurement, cardiovascular disease, diabetes, and elevated mortality. Effective treatment is critical not just for symptom relief but for restoring life expectancy to population norms.
This comprehensive 2025 review from Brazilian neuroendocrinology experts at Universidade Federal do Rio de Janeiro synthesizes the current treatment landscape. Surgery remains first-line, achieving cure in approximately 50% of patients at experienced reference centers. For those who fail surgery or are not surgical candidates, three drug classes are available: somatostatin receptor ligands (SRLs, the most commonly used), dopamine agonists, and growth hormone receptor antagonists such as pegvisomant.
Despite decades of progress, roughly 40% of patients do not achieve adequate disease control with available medications. Even among those who do reach biochemical targets, quality of life frequently remains compromised and the treatment burden — including injection schedules and monitoring — remains substantial. This gap underscores a clear unmet need for more efficacious agents and more convenient delivery options.
The review details a promising pipeline of investigational therapies in various development phases, pointing toward next-generation molecules that may offer superior efficacy or improved tolerability. Crucially, the authors advocate for a precision medicine framework: using biomarkers to predict individual patient responses to specific therapies, replacing the current largely empirical approach.
While the review is narrative and based primarily on existing literature without new clinical data, its scope and the authors' deep clinical expertise lend it considerable authority. The call for biomarker-guided therapy selection aligns with broader trends across endocrinology and oncology, and could meaningfully reshape how acromegaly is managed in coming years.
Key Findings
- Surgery cures ~50% of acromegaly patients at reference centers; the rest require medical therapy.
- Approximately 40% of patients fail to achieve biochemical control with current drug classes.
- Quality of life remains impaired in many patients even after biochemical normalization.
- A pipeline of new drugs in various development phases may address current efficacy and convenience gaps.
- Precision medicine using predictive biomarkers could replace the current trial-and-error prescribing approach.
Methodology
This is a narrative review article published in Endocrine Reviews, a high-impact endocrinology journal. The authors synthesize existing clinical literature, trial data, and pipeline drug information rather than presenting new primary data. No systematic review protocol or meta-analytic methods are described.
Study Limitations
The review is based only on the abstract, so the full breadth of specific pipeline agents, biomarker evidence, and clinical data cannot be assessed. As a narrative review, it may reflect author interpretation and selection bias rather than a systematic appraisal of all evidence. No new clinical trial data are presented.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.